US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eisai Co., Ltd.

7.35

+0.15002.08%

Volume:59.87K

Turnover:432.95K

Market Cap:8.36B

PE:41.53

High:7.35

Open:6.89

Low:6.89

Close:7.20

52wk High:9.22

52wk Low:5.94

Shares:1.14B

Float Shares:1.08B

Volume Ratio:0.38

T/O Rate:0.01%

Dividend:0.27

Dividend Rate:3.63%

EPS(TTM):0.1770

EPS(LYR):0.2444

ROE:5.90%

ROA:2.43%

PB:1.54

PE(LYR):30.08

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Eisai, Biogen announces FDA accepted to review the sBLA for lecanemab-irmb

Nuvation Bio, Eisai enter exclusive taletrectinib license agreement

The miracle of curing Alzheimer's? No longer an impossibility.

This Medicare premium just crossed $200 for the first time. Here's why.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ESAIY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ESAIY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ESAIY\",,,,,undefined,":{"symbol":"ESAIY","market":"US","secType":"STK","nameCN":"Eisai Co., Ltd.","latestPrice":7.35,"timestamp":1770411600000,"preClose":7.2,"halted":0,"volume":59866,"delay":15,"changeRate":0.02083333333333326,"floatShares":1076747898,"shares":1137465824,"eps":0.176978,"marketStatus":"Market Closed","change":0.15,"latestTime":"02-06 16:00:00 EST Delay","open":6.89,"high":7.35,"low":6.89,"amount":432950.3114,"amplitude":0.063889,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.176978,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0.25,"exchange":"PINK LIMITED","adjPreClose":7.2,"volumeRatio":0.3763069789730775},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ESAIY\",,,,,undefined,":{"symbol":"ESAIY","floatShares":1076747898,"roa":"2.43%","roe":"5.90%","lyrEps":0.244385,"volumeRatio":0.3763069789730775,"shares":1137465824,"dividePrice":0.267,"high":7.35,"amplitude":0.063889,"preClose":7.2,"low":6.89,"week52Low":5.94,"pbRate":"1.54","psRate":"1.63","week52High":9.22,"institutionHeld":0,"latestPrice":7.35,"eps":0.176978,"divideRate":0.036327,"volume":59866,"delay":15,"ttmEps":0.176978,"open":6.89,"prevYearClose":7.38,"prevWeekClose":6.91,"prevMonthClose":6.91,"prevQuarterClose":7.38,"fiveDayClose":6.91,"twentyDayClose":7.53,"sixtyDayClose":7.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ESAIY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-06","symbol":"ESAIY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738818000000,"reportTimeType":"post","actualEps":null},{"date":"2024-08-01","symbol":"ESAIY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722542400000,"name":null,"time":"Post Market","dateTimestamp":1722484800000,"actualEps":null},{"date":"2024-05-14","symbol":"ESAIY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715716800000,"name":null,"time":"Post Market","dateTimestamp":1715659200000,"actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ESAIY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-07","symbol":"ESAIY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1699333200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ESAIY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ESAIY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1333,"buy":0.1333,"hold":0.6667,"sell":0.0667,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":15,"updateTime":1769576400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ESAIY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606267013","title":"Eisai, Biogen announces FDA accepted to review the sBLA for lecanemab-irmb","url":"https://stock-news.laohu8.com/highlight/detail?id=2606267013","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606267013?lang=en_us&edition=fundamental","pubTime":"2026-01-26 10:15","pubTimestamp":1769393716,"startTime":"0","endTime":"0","summary":"Eisai (ESAIY) and Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has accepted for review Eisai’s Supplemental Biologics L...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eisai-biogen-announces-fda-accepted-to-review-the-sbla-for-lecanemab-irmb-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eisai-biogen-announces-fda-accepted-to-review-the-sbla-for-lecanemab-irmb-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE00B19Z9P08.USD","LU0320765992.SGD","LU0889565916.HKD","BK4588","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","LU0109394709.USD","BK4139","BIIB","ESAIY","BK4007","BK4533","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2602100775","title":"Nuvation Bio, Eisai enter exclusive taletrectinib license agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2602100775","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602100775?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:06","pubTimestamp":1768223197,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) and Eisai (ESAIY) announced an exclusive license and collaboration agreement that significantly expands the long-term global fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-eisai-enter-exclusive-taletrectinib-license-agreement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-eisai-enter-exclusive-taletrectinib-license-agreement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESAIY","BK4007","NUVB"],"gpt_icon":0},{"id":"2595732211","title":"The miracle of curing Alzheimer's? No longer an impossibility.","url":"https://stock-news.laohu8.com/highlight/detail?id=2595732211","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595732211?lang=en_us&edition=fundamental","pubTime":"2025-12-30 02:21","pubTimestamp":1767032460,"startTime":"0","endTime":"0","summary":"More research shows the disease may one day be reversible. Recent science on Alzheimer's disease provides cause for optimism.A new scientific breakthrough in the field of Alzheimer's research is raising hopes that the cruel, crippling and fatal brain disease may eventually become curable.An international team of more than 35 scientists from some of the world's leading institutions have published new research showing \"proof of principle\" that advanced Alzheimer's disease - often characterized not only by the loss of memory and executive function, but of one's actual personality - could be \"reversible.\". \"Alzheimer's disease can be reversed to achieve full neurological recovery - not just prevented or slowed - in animal models,\" according to researchers at Case Western Reserve University in Cleveland, whose scientists helped lead the investigation.Mice who were administered a regular course of a pharmacological agent called P7C3-A20 experienced \"full cognitive recovery\" even if they alre","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B19Z9P08.USD","BK4533","IE00B894F039.SGD","BK4585","BK4139","IE00B19Z9Z06.USD","LU0109394709.USD","LU0320765992.SGD","BIIB","ESAIY","BK4532","LU0234570918.USD","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2585172253","title":"This Medicare premium just crossed $200 for the first time. Here's why.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585172253","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585172253?lang=en_us&edition=fundamental","pubTime":"2025-11-22 21:30","pubTimestamp":1763818200,"startTime":"0","endTime":"0","summary":"The 9.7% increase in the cost of Medicare Part B premiums for 2026 is due to several factors, including projected growth in Medicare Advantage and outpatient care next year. Medicare Part B premiums are going up by 9.7% in 2026.Blame medical inflation and more people in need of costly care for the 9.7% jump in Medicare Part B premiums next year.Starting in January, people on Medicare will pay $202.90 in 2026 for their monthly Part B premiums, which provide coverage for services like doctor's visits, outpatient procedures and medications administered by a healthcare professional. That's up from $185.00 in 2025.The government has a simple explanation for the largest-ever dollar increase for these premiums, citing \"projected growth in overall healthcare spending.\" Medicare's spending growth is supposed to increase 8.9% across 2026 and 2027, outpacing the 5.6% jump in predicted health spending growth in general.Plus, more care is moving from inpatient settings to less expensive outpatient ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","MRK","LU1571399168.USD","LU1023059063.AUD","SG9999001176.SGD","LU2362540622.SGD","BK4588","IE00BLSP4239.USD","LU0106261372.USD","LU0320765646.SGD","LU2346227817.USD","LU2461242641.AUD","IE00B1BXHZ80.USD","LU1066051498.USD","BK4516","LU0553294199.USD","LU0985320562.USD","LU1941712348.USD","LU2362541273.HKD","CMS","LU0823416689.USD","LU0070302665.USD","BK4139","REGN","LU0965509101.SGD","LU1430594728.SGD","ESAIY","SG9999002232.USD","BK4585","BK4559","LU0208291251.USD","LU2106854487.HKD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0265550946.USD","LU2361045086.USD","LU2468319806.SGD","LU1035773651.USD","LU1069347547.HKD","IE00B4R5TH58.HKD","IE00BSNM7G36.USD","BK4550","LU0122379950.USD","SG9999002224.SGD","LU1917777945.USD","LU0965508806.USD","LU1093756325.SGD","IE00B2B36J28.USD","LU1093756168.USD","LU1934455863.HKD"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ESAIY\",params:#limit:6,delay:false,,,undefined,":[]}}